We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.55 | 1.12% | 49.50 | 49.95 | 50.26 | 50.59 | 48.65 | 48.71 | 2,131,999 | 00:52:23 |
From May 2019 to May 2024
By Inti Landauro
PARIS-- French drug giant Sanofi (SAN.FR) and U.S. partner Regeneron Pharmaceuticals (REGN) said a one-year phase three trial study showed a treatment combining their drug dupilumab with topical corticosteroids significantly improved the situations of a group of patients suffering from atopic dermatitis.
The treatment including dupilumab improved the overall severity of the disease for patients whose atopic dermatitis was inadequately controlled by a treatment of just topical corticosteroids, the companies said Monday.
The patients who took the dupilumab treatment were compared with another group of similar patients who took topical corticosteroids and a placebo.
Large pharmaceutical labs like Sanofi are rushing to develop new drugs to replace a number of existing drugs that are entering the public domain, which would allow generic pharmaceutical groups to produce and sell the same drugs at a fraction of the current price, a phenomenon known as the "patent cliff."
-Write to Inti Landauro at inti.landauro@wsj.com
(END) Dow Jones Newswires
June 06, 2016 01:48 ET (05:48 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
